Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
Public ClinicalTrials.gov record NCT02147951. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Expanded access of Talimogene Laherparepvec for subjects with unresected, stage IIIb to IVM1c Melanoma.
Study identification
- NCT ID
- NCT02147951
- Recruitment status
- No Longer Available
- Study type
- Expanded access
- Phase
- Not listed
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 95 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Feb 29, 2016
United States locations
- U.S. sites
- 24
- U.S. states
- 17
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Mobile | Alabama | 36604 | — |
| Research Site | Mobile | Alabama | 36608 | — |
| Research Site | Little Rock | Arkansas | 72205 | — |
| Research Site | Duarte | California | 91010 | — |
| Research Site | La Jolla | California | 92093-0698 | — |
| Research Site | Daytona Beach | Florida | 32117 | — |
| Research Site | Jacksonville | Florida | 32207 | — |
| Research Site | Miami Beach | Florida | 33140 | — |
| Research Site | Indianapolis | Indiana | 46260 | — |
| Research Site | Louisville | Kentucky | 40202 | — |
| Research Site | Minneapolis | Minnesota | 55407 | — |
| Research Site | St Louis | Missouri | 63110-1093 | — |
| Research Site | Omaha | Nebraska | 68130 | — |
| Research Site | Omaha | Nebraska | 68198 | — |
| Research Site | Morristown | New Jersey | 07962 | — |
| Research Site | New York | New York | 10016 | — |
| Research Site | Winston-Salem | North Carolina | 27157 | — |
| Research Site | Canton | Ohio | 44718 | — |
| Research Site | Portland | Oregon | 97213 | — |
| Research Site | Greenville | South Carolina | 29605 | — |
| Research Site | Dallas | Texas | 75230 | — |
| Research Site | Dallas | Texas | 75390 | — |
| Research Site | Franklin | Wisconsin | 53132 | — |
| Research Site | Wauwatosa | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02147951, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 29, 2016 · Synced Sep 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02147951 live on ClinicalTrials.gov.